NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies

February 13, 2019 – New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. The guidelines, which take into consideration the clinical evidence that the FDA evaluated in approving novel agents and new indications for existing drugs, are commonly used as a baseline in … (leggi tutto)